Panzyga in CIDP Administered at Different Infusion Rates
Status:
Unknown status
Trial end date:
2018-12-15
Target enrollment:
Participant gender:
Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral
neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune
globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit,
taking up resources such as nursing time and hospital space. Chronic treatment is required in
most cases.